This nanomedicine effectively decreased tumor growth and angiogenesis both in vitro and in breast cancer xenografts by impacting the signal transducer and activator of the transcription 3 (STAT3)/vascular endothelial growth factor (VEGF) signaling axis. The gene discussed is VEGFA; the disease is breast carcinoma.